ATRC Sees 18-21% Revenue Growth, EVH Q2 Results Beat Estimates, EXAS Trims Outlook, HRMY On Watch...

Rigel Pharmaceuticals Inc. (RIGL) expects to report top-line results from a pivotal phase III clinical trial evaluating Fostamatinib in high-risk patients hospitalized with COVID-19 in the fourth quarter of this year.

from RTT - Top Story https://ift.tt/oPljdxH
via IFTTT